Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down - Here's Why

Key Points

• Regeneron Pharmaceuticals (NASDAQ:REGN) experienced a significant drop in share price, opening at $580.00 after closing at $595.68, and last traded at $577.28.
• Analysts have varied opinions on the stock, with a consensus rating of "Moderate Buy" and a target price of $817.67, reflecting a mix of assessments from different financial institutions.
• The company reported strong quarterly earnings with $12.89 earnings per share, significantly beating expectations, and a corresponding revenue of $3.68 billion for the quarter.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $595.68, but opened at $580.00. Regeneron Pharmaceuticals shares last traded at $577.28, with a volume of 170,872 shares.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Trading Down 4.6%

The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market cap of $60.23 billion, a P/E ratio of 14.32, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35. The stock has a 50-day moving average of $568.27 and a two-hundred day moving average of $573.48.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the company earned $11.56 EPS. The firm's revenue for the quarter was up 3.6% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Caldwell Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $51,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $31,000. Valeo Financial Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 51.3% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,797 shares of the biopharmaceutical company's stock worth $944,000 after buying an additional 609 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company's stock worth $9,607,000 after buying an additional 6,073 shares during the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $1,138,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.